MRK - Merck & Co., Inc.
| Previous close | 73.92 |
| Open | 73.48 |
| Bid | 73.30 x 3100 |
| Ask | 73.75 x 1100 |
| Day's range | 72.23 - 74.05 |
| 52-week range | 56.26 - 83.85 |
| Volume | 30,109,223 |
| Avg. volume | 10,954,412 |
| Market cap | 189.056B |
| Beta (3Y monthly) | 0.37 |
| PE ratio (TTM) | 31.55 |
| EPS (TTM) | 2.32 |
| Earnings date | 30 Apr 2019 |
| Forward dividend & yield | 2.20 (2.65%) |
| Ex-dividend date | 2019-03-14 |
| 1y target est | 87.36 |
- Zacks•yesterday
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
- Zacks•yesterday
Can Q1 Earnings Lift Healthcare ETFs Higher?
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
- Zacks•yesterday
Here Are the Key Takeaways From J&J's Q1 Earnings Report
Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.
- Zacks•yesterday
Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
- Reuters•2 days ago
RPT-US STOCKS-Wall Street slips, weighed down by healthcare plunge
- Reuters•2 days ago
US STOCKS-Wall Street slides, dragged down by healthcare
Plunging healthcare stocks dragged Wall Street lower on Wednesday, offsetting a spate of upbeat corporate earnings and encouraging economic data from the United States and China. All three major U.S. stock indexes were down, but the S&P 500 slipped to more than a percent below its record high reached in September.
- Reuters•2 days ago
CORRECTED-US STOCKS-Wall St dips as healthcare slide offsets chip boost
U.S. stocks headed lower on Wednesday, as a selloff in healthcare stocks extended for a second day, overshadowing a rally in chipmakers led by Qualcomm. Medical device maker Abbott Laboratories Inc fell 3.8%, despite quarterly results beating estimates. UnitedHealth Group Inc, Pfizer Inc and Merck & Co fell more than 2% and were the biggest drags on the broader S&P 500 index.
- Zacks•2 days ago
Top Analyst Reports for Wells Fargo, UnitedHealth & Merck
Top Analyst Reports for Wells Fargo, UnitedHealth & Merck
- Zacks•2 days ago
Gilead Collaborates With Insitro to Develop NASH Therapies
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
- Zacks•3 days ago
J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
- Zacks•3 days ago
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks•4 days ago
Merck (MRK) Dips More Than Broader Markets: What You Should Know
Merck (MRK) closed the most recent trading day at $78.53, moving -1.13% from the previous trading session.
- Zacks•4 days ago
Bristol-Myers' Shareholders Vote for Celgene Acquisition
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
- Zacks•4 days ago
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
- Business Wire•6 days ago
Results of Phase 3 Trial Evaluating Merck’s ZERBAXA® (ceftolozane and tazobactam) versus Meropenem for Treatment of Adult Patients with Ventilated Nosocomial Pneumonia (VNP) to be Presented at ECCMID 2019
Merck (MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA® (ceftolozane and tazobactam) for the treatment of adult patients with ventilated nosocomial (hospital acquired) pneumonia. The results demonstrated non-inferiority of an investigational dose of ZERBAXA to meropenem, the active comparator, in the primary and key secondary endpoints.
- Zacks•7 days ago
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
- Zacks•7 days ago
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Reuters•7 days agoMerck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals
Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.
- Business Wire•8 days ago
FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)
KEYTRUDA Now Approved for First-Line Treatment of Patients with Stage III NSCLC Who Are Not Candidates for Surgical Resection or Definitive Chemoradiation, or Metastatic NSCLC, and
- Reuters•8 days ago
US STOCKS-Wall St dips ahead of big bank earnings
The S&P financial index rose 0.54%, while the banking sector was up 0.36%. Earnings of S&P 500 bank are expected to grow 1.8% in the first quarter, well below 8.2% estimated six months ago, according to Refinitiv data. The steep drop in the estimate comes in the wake of the Federal Reserve's dovish tilt and the subsequent drop in 10-year Treasury yields.
- Zacks•8 days ago
Intercept Reports Additional Positive Data From NASH Study
Intercept Pharmaceuticals (ICPT) reports positive additional supportive data from its phase III REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH.
- Zacks•8 days ago
Seattle Genetics' Adcetris Progresses Well Amid Competition
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
- Motley Fool•9 days ago
What the New York City Measles Emergency Means For Vaccine-Maker Merck
Here's how the pharma giant fits in with the latest outbreak and the city's major response.
- Zacks•9 days ago
Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval
Amgen (AMGN) gets approval in the United States for osteoporosis drug, Evenity.
- Zacks•9 days ago
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
